N/A N=80 Randomized Supportive Care

Mobile Continuing Care Approach for Youth

Addiction

Bottom Line

View on ClinicalTrials.gov: NCT01632735 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2015

Primary outcome: Primary: Primary Substance Use (Defined as Substance Received Treatment for) — 47.5; 41.5; 14.7; 62.9 percentage of positive urines — p=<0.05

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Mobile Continuing Care (Behavioral)
Age: Pediatric, Adult · 12+ yrs
Sex: All
Sponsor: Azusa Pacific University
Primary completion: Dec 2014

Outcome Measures

Outcome	Result	p-value
PRIMARY Primary Substance Use (Defined as Substance Received Treatment for)	47.5; 41.5; 14.7; 62.9; 21.4; 59.3	<0.05 sig
SECONDARY Participation in Recovery Behaviors Over Time	12.1; 14.5; 17.3; 10.3; 14.5; 11.97	<0.001 sig
SECONDARY Recovery Confidence (Self-efficacy) Over Time	2.40; 2.53; 2.73; 2.57; 2.67; 2.43	<0.001 sig
SECONDARY Social Support Utilization	12.8; 9.8; 8.6; 2.8; 7.4; 2.4	<0.001 sig

Summary

The primary purpose of this study is to test the effectiveness of a pilot mobile based continuing care program (monitoring/feedback texting) relative to standard continuing care as usual in reducing relapse and improving psychosocial functioning outcomes in a youth population (under 24) with substance abuse problems.

Eligibility Criteria

Inclusion Criteria

Youth between 12 and 24 years old
Youth in treatment for substance abuse
Youth who complete treatment (minimum 12 weeks)
Youth who have the cognitive capacity to understand study procedures and agree to participate

Exclusion Criteria

Presence of an adverse (life threatening) medical condition that could interfere with study participation.
Presence of psychiatric co-occurring illness or symptoms warranting safety concerns or continued treatment, including acute suicide risk; and
Current homelessness (unless residing in recovery home for which contact information can be provided).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01632735). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.